This implies that passive immunization with tau antibodies can be a viable therapeutic focus on and that the CSF amount of p-tau262/356 or on the microtubule binding area (MTBD) can serve as a valuable biomarker of tau pathology to watch tau therapeutics in clinical trials.Through the La Biennale di Venezia Web site: “Her fantastical bodies expan